Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2258748 | 0.95 | EPHX2 (0.67) | EPHX2CYP2C9CHRM1CHRM3P2RX7 | |
| SCHEMBL13882323 | 0.88 | EPHX2 (0.58) | EPHX2CYP2C9P2RX7 | |
| SCHEMBL2241728 | 0.80 | EPHX2 (0.58) | EPHX2CYP2C9P2RX7 | |
| SCHEMBL2241735 | 0.80 | EPHX2 (0.58) | EPHX2CYP2C9P2RX7 | |
| SCHEMBL14068289 | 0.80 | EPHX2 (0.58) | EPHX2CYP2C9P2RX7 | |
| SCHEMBL2679093 | 0.80 | EPHX2 (0.61) | EPHX2CYP2C9 | |
| Hydrochloric Acid SCHEMBL30924066 | 0.80 | EPHX2 (0.70) | EPHX2P2RX7 | |
| SCHEMBL2679089 | 0.80 | EPHX2 (0.61) | EPHX2CYP2C9 | |
| SCHEMBL12095818 | 0.79 | EPHX2 (0.60) | EPHX2CYP2C9P2RX7 | |
| Hydrochloric Acid SCHEMBL30924163 | 0.79 | EPHX2 (0.69) | EPHX2CHRM1CHRM3P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | GLAXOSMITHKLINE LLC | 2010-12-23 | — | — | US | disclosed |
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | SMITHKLINE BEECHAM CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311775-A1 | Novel sEH Inhibitors and Their Use | EPHX1, NCEH1, FAH | EPHX2 4/4885CYP2C9 160/4885CHRM1 3417/4885 |
| US-20100324076-A1 | Novel sEH Inhibitors and their Use | EPHX1, NCEH1, PCSK9 | EPHX2 5/4885CYP2C9 201/4885CHRM1 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.